Dermatofibroma differential diagnosis
|
Dermatofibroma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dermatofibroma differential diagnosis On the Web |
|
American Roentgen Ray Society Images of Dermatofibroma differential diagnosis |
|
Risk calculators and risk factors for Dermatofibroma differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Deep penetrating dermatofibroma may be difficult to distinguish, even histologically, from rare malignant fibrohistocytic tumors e.g dermatofibrosarcoma protuberans[1]
Differential Diagnosis
- Deep penetrating dermatofibroma may be difficult to distinguish, even histologically, from rare malignant fibrohistocytic tumors e.g dermatofibrosarcoma protuberans[2]
Immunohistochemical Staining
| Neoplasm | CD34 | Stromelysin-3[3] | Factor XIIIa |
|---|---|---|---|
| Dermatofibroma | + | + | + |
| Dermatofibrosarcoma protuberans | + | - | - |
References
- ↑ Hanly AJ, Jordà M, Elgart GW, Badiavas E, Nassiri M, Nadji M (2006). "High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors". Arch. Pathol. Lab. Med. 130 (6): 831–4. doi:10.1043/1543-2165(2006)130[831:HPAEDR]2.0.CO;2. PMID 16740036. Unknown parameter
|month=ignored (help) - ↑ Hanly AJ, Jordà M, Elgart GW, Badiavas E, Nassiri M, Nadji M (2006). "High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors". Arch. Pathol. Lab. Med. 130 (6): 831–4. doi:10.1043/1543-2165(2006)130[831:HPAEDR]2.0.CO;2. PMID 16740036. Unknown parameter
|month=ignored (help) - ↑ Kim HJ, Lee JY, Kim SH; et al. (2007). "Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34". Br. J. Dermatol. 157 (2): 319–24. doi:10.1111/j.1365-2133.2007.08033.x. PMID 17596171. Unknown parameter
|month=ignored (help)